Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT00354120

Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant (GLOBAL)

Randomized Study for Comparison of Reduced Intensity Conditioning Protocols Containing Either Thymoglobuline or Alemtuzumab in Patients Undergoing Allogeneic Transplant From Voluntary Unrelated Donors

Sponsor: Gruppo Italiano Trapianto di Midollo Osseo

Conditions Acute Myeloblastic Leukemia Chronic Myeloid Leukemia Lympho-proliferative Diseases Lymphoblastic Leukemia Myelodysplasia Myelofibrosis

Interventions Alentuzumab Globulina antilinfocitaria

Updated 7 times since 2017 Last updated: Mar 9, 2023 Started: Mar 31, 2005 Primary completion: Aug 31, 2011 Completion: Aug 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Acute Myeloblastic Leukemia and Chronic Myeloid Leukemia and is currently completed. Gruppo Italiano Trapianto di Midollo Osseo leads this study, which shows 7 recorded versions since 2005 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2/PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Apr 2023 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jan 2021 — Apr 2023 [monthly]

Completed PHASE2_PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gruppo Italiano Trapianto di Midollo Osseo

Data source: Gruppo Italiano Trapianto di Midollo Osseo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alessandria, Italy , Ancona, Italy , Bergamo, Italy , Cuneo, Italy , Florence, Italy , Genova, Italy , Milan, Italy , Modena, Italy , Monza, Italy , Palermo, Italy and 9 more locations